Factors associated with lenvatinib adherence in thyroid cancer and hepatocellular carcinoma.

Yoshikazu Tateai Kazuyoshi KawakamiMinori TeramaeNaoki FukudaTakashi YokokawaKazuo KobayashiNaoki ShibataWataru SuzukiHisanori ShimizuShunji TakahashiMasato OzakaNaoki SasahiraSatoko HoriMasakazu Yamaguchi

Published in: PloS one (2023)

The adherence rate for lenvatinib in Japanese patients with thyroid and hepatocellular carcinoma in real-world clinical practice was more than 90% in this study. Hypertension was a major reason for non-adherence, followed by hand-foot skin reactions and diarrhea.

Keyphrases

clinical practice
blood pressure
glycemic control
type diabetes
adipose tissue
weight loss
irritable bowel syndrome